Do foetal transplant studies continue to be justified in Huntington's disease?

Bartley, Oliver J M, Lelos, Mariah J ORCID: https://orcid.org/0000-0001-7102-055X, Gray, William P ORCID: https://orcid.org/0000-0001-7595-8887 and Rosser, Anne E ORCID: https://orcid.org/0000-0002-4716-4753 2021. Do foetal transplant studies continue to be justified in Huntington's disease? Neuronal Signaling 5 , acerbic. 10.1042/NS20210019

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (335kB) | Preview

Abstract

Early CNS transplantation studies used foetal derived cell products to provide a foundation of evidence for functional recovery in preclinical studies and early clinical trials. However, it was soon recognised that the practical limitations of foetal tissue make it unsuitable for widespread clinical use. Considerable effort has since been directed towards producing target cell phenotypes from pluripotent stem cells (PSC) instead, and there now exist several publications detailing the differentiation and characterisation of PSC derived products relevant for transplantation in Huntington’s disease (HD). In light of this progress, we ask if foetal tissue transplantation continues to be justified in HD research. We argue that (i) the extent to which accurately differentiated target cells can presently be produced from PSCs is still unclear, currently making them undesirable for studying wider CNS transplantation issues; (ii) foetal derived cells remain a valuable tool in pre-clinical research for advancing our understanding of which products produce functional striatal grafts and as a reference to further improve PSC derived products; and (iii) until PSC derived products are ready for human trials, it is important to continue using foetal cells to gather clinical evidence that transplantation is a viable option in HD and to use this opportunity to optimise practical parameters (such as trial design, clinical practices, and delivery strategies) to pave the way for future PSC derived products.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Neuroscience and Mental Health Research Institute (NMHRI) Biosciences
Publisher:	Portland Press
ISSN:	2059-6553
Funders:	MRC
Date of First Compliant Deposit:	23 November 2021
Date of Acceptance:	22 November 2021
Last Modified:	14 Sep 2024 01:30
URI:	https://orca.cardiff.ac.uk/id/eprint/145700

Actions (repository staff only)

Edit Item